Purpose: The purpose of this study is to evaluate the long-term efficacy of supraciliary micro-stent implantation in combination with phacoemulsification in the treatment of mild-moderate primary open angle glaucoma (POAG). Methods: Retrospective data of patients previously enrolled in the “Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery” (COMPASS trial), in which patients with mild-moderate POAG had undergone either cataract surgery alone or cataract surgery combined with implantation of a supraciliary micro-stent, were collected. Eligible patients had since exited the trial and had 5-8 years of postoperative data available. The primary outcome measure was the proportion of eyes with a “complete success” defined as an IOP ≤ 18 mmHg on no glaucoma medications and not having undergone any secondary surgical procedures for IOP control. Thirty-three eyes were in the treatment group and 12 eyes were in the control group. Device safety was also reviewed. Results: Significantly more eyes in the treatment group achieved a “complete success” (61%) versus those eyes in the control group (17%) (p\u3c0.05). When controlling for patient age, sex, preoperative visual field, preoperative IOP, and preoperative anti-glaucoma medication usage, eyes in the treatment groups were 9 times more likely to meet the primary outcome measure versus control group (p=0.004). Mean postoperative IOP was 17.7 ± 4.8 in the control group versus 15.0 ± 4.4 in the treatment group (p=0.08), while mean medication usage was 0.9 ± 0.7 in the control group versus 0.4 ± 0.7 in the treatment group (p=0.01). Average follow up was 6.38 years. No device related adverse events, such as corneal decompensation occurred. Conclusion: Implantation of a supraciliary micro-stent combined with cataract surgery in eyes with mild-moderate POAG demonstrates better long term IOP control than those eyes undergoing cataract surgery alone
